William Waddill Sells 20,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 20,000 shares of Protagonist Therapeutics stock in a transaction on Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $654,796. This represents a 71.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Protagonist Therapeutics Stock Up 4.7%

PTGX opened at $84.49 on Friday. The stock has a market cap of $5.28 billion, a P/E ratio of 136.28 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $96.54. The company has a fifty day simple moving average of $85.65 and a 200 day simple moving average of $73.80.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million during the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. On average, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on PTGX shares. Citizens Jmp lifted their price target on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. BTIG Research reaffirmed a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Truist Financial lifted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Finally, Wedbush lifted their price objective on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $91.64.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its position in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at about $27,000. Bessemer Group Inc. lifted its stake in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the last quarter. Salomon & Ludwin LLC bought a new position in Protagonist Therapeutics during the third quarter worth about $29,000. Finally, CWM LLC grew its holdings in Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after purchasing an additional 407 shares during the period. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.